rethinkTHC Search
Menu
Evidence in context

Cannabis and Depression

The research base for cannabis and depression includes 193 peer-reviewed studies spanning 2001–2026. Of these, 30 provide strong evidence, including 7 meta-analyses and 6 randomized controlled trials.

Published summary: 2026-03-07

Where the evidence converges

Across 22 longitudinal cohorts, cannabis use was linked to about 29 percent higher odds of later depression, with exposure measures often weak and overall bias rated medium

Strong evidence · 7 studies

Observational evidence only. Even with baseline adjustment, unmeasured confounding can explain part of the signal. Cannabis exposure was inconsistently measured, often as any use versus none, with lit

A Lancet meta-analysis of 83 studies found scarce evidence that cannabinoids help depression, anxiety, PTSD, or other mental disorders, with THC products doubling adverse event rates versus placebo

Strong evidence · 7 studies

Most included RCTs examined THC-based pharmaceuticals, not CBD or whole-plant cannabis. Many conditions had very few RCTs (Tourette: 2 RCTs n=36; PTSD: 1 RCT n=10; ADHD: 1 RCT n=30). The evidence was

Meta-analysis of 23,317 individuals found adolescent cannabis use linked to 37% higher depression risk and 3

Strong evidence · 7 studies

Observational studies cannot prove causation. Residual confounding possible despite adjustment for baseline mental health. Suicide attempt association had high heterogeneity (I2=61.3%). Dose-response

Where questions remain

Over 15 years, cannabis abusers were four times more likely to develop depression including suicidal thoughts

Moderate evidence · 34 studies

The 15-year gap between assessments means intervening variables could explain the association. Cannabis "abuse" is a specific diagnostic category that may not represent all use patterns. The baseline

Twin study of 3,360 male pairs finding that the genetic link between depression and cannabis/alcohol dependence was largely explained by shared genetic risk for antisocial personality disorder

Moderate evidence · 34 studies

The sample was limited to male veterans, who may not represent the general population. The Vietnam Era Twin Registry overrepresents men exposed to military service during a specific historical period.

Comprehensive review found strong evidence linking cannabis to psychosis, supported the existence of cannabis withdrawal syndrome, and called for more rigorous research on prevention and treatment

Moderate evidence · 34 studies

As a narrative review, it did not systematically grade the quality of evidence for each claim. The causal direction of the cannabis-mental health relationship was acknowledged as uncertain. Prevention

Study of 119 heavy cannabis users found high rates of depression (46%) and suicidality (42%), predicted by parental alcoholism and childhood adversity rather than cannabis or other drug use

Moderate evidence · 34 studies

Treatment-seeking population may not represent all heavy cannabis users. Cross-sectional design cannot establish causation. Self-reported childhood experiences may be affected by current mental state

Research gaps

  • Only 6 randomized controlled trials exist out of 193 studies — most evidence is observational or from reviews.
  • Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
  • Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.

Key studies

Meta-analysis: youth cannabis use linked to 28-87% higher odds of depression, anxiety, and suicidal behavior

Young people are the largest cannabis consumer demographic and also the population most vulnerable to mental health disruptions. This meta-analysis quantifies the magnitude of the mental health risks associated with cannabis use during this critical developmental period.

Cannabis Use Was Linked to Suicidal Behavior Even After Accounting for Depression, Though Depression Partly Explains the Connection

The cannabis-suicide link has been debated, with critics arguing depression explains it entirely. This meta-analysis shows the association persists even after accounting for depression in many studies, while also acknowledging that depression does partly confound the relationship.

Cannabis use more than doubled the risk of suicide attempt in youth ages 11-21

Cannabis is the most frequently consumed drug among young people worldwide. Quantifying its association with suicide behaviors in this vulnerable age group informs prevention priorities.

How common is it to have both cannabis use disorder and depression or anxiety?

The threefold co-occurrence of cannabis use disorder with depression and anxiety underscores the complexity of treating either condition in isolation. Integrated treatment approaches may be needed for this substantial overlap.

A major Lancet review found little evidence that cannabinoids help mental disorders and increased side effects

This is the most comprehensive meta-analysis of cannabinoids for mental disorders published in a top-tier psychiatric journal. Its sobering conclusions challenge the widespread assumption that cannabis-based medicines are broadly effective for mental health conditions.

Adolescent cannabis use linked to 37% higher depression risk and 3.5x higher suicide attempt risk in young adulthood

Published in JAMA Psychiatry, this is one of the most rigorous analyses of the adolescent cannabis-depression link. The elevated suicide attempt risk is particularly concerning given the high prevalence of adolescent cannabis use worldwide.

How the research developed

2000–2009

12 studies published. Includes 1 RCTs, 4 strong-evidence studies.

2010–2014

12 studies published. Includes 1 meta-analyses, 1 RCTs, 1 strong-evidence studies.

2015–2019

32 studies published. Includes 2 meta-analyses, 4 strong-evidence studies.

2020–present

137 studies published. Includes 4 meta-analyses, 4 RCTs, 21 strong-evidence studies.

How this summary was assembled

This consensus synthesizes 193 peer-reviewed studies: 7 meta-analyses (4%), 6 randomized controlled trials (3%), 72 observational studies (37%), 31 reviews (16%), 3 case studies (2%), 74 other study types (38%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.

These counts describe the source summary at publication. They may differ from the current library.